High Blood Pressure Should Not Rule Out Clot-Busting Stroke Treatment

	Tweet

Patients who require therapy to lower their blood pressure following a stroke do not appear to be at a higher risk for bleeding or other adverse outcomes after receiving anti-clotting therapy, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

Patients who have an acute ischemic stroke - in which a clot blocks blood flow to the brain - often have elevated blood pressure, according to background information in the article. “As many as 10 percent of otherwise eligible patients do not receive tissue plasminogen activator (tPA), the only proved therapy for acute ischemic stroke, because of severely elevated blood pressure,” the authors write. “In the past, guidelines recommended against giving tPA to treat acute ischemic stroke when aggressive measures (such as continuous infusion or more than two infusions of anti-hypertensive agents) are required to maintain blood pressure lower than 185/110 millimeters of mercury.”

Sheryl Martin-Schild, M.D., Ph.D., then of the University of Texas Health Sciences Center at Houston and now of Tulane University Health Sciences Center, New Orleans, and colleagues reviewed the medical records of 178 patients with acute ischemic stroke who received intravenous tPA within three hours. Of these, 50 required treatment for lowering blood pressure before beginning tPA therapy. This included 24 (48 percent) who received the medication nicardipine, either alone or in combination with the drug labetalol.

“We observed several important differences between patients who required blood pressure–lowering treatment and those who did not,” the authors write. “They had more severe strokes and their blood glucose concentration was higher, predicting they would have a worse outcome if all other factors were equal. As expected, they more frequently had a history of hypertension.”

After controlling for these factors—including age, baseline stroke severity and blood glucose levels—there were no differences between patients who received antihypertensive treatments and those who didn’t in adverse events, poor outcomes or stroke severity scores at discharge.

“Overall, the results of the present study provide the first experimental support for the revised American Heart Association guidelines allowing tPA therapy in patients requiring aggressive blood pressure management and also provides support for the use of nicardipine in patients with acute ischemic stroke who are eligible for thrombolytic therapy,” the authors conclude. “Aggressive control of severely elevated blood pressure is feasible and should not automatically exclude otherwise eligible patients with acute ischemic stroke from receiving thrombolytic therapy.”
(Arch Neurol. 2008;65[9]:1174-1178. Available pre-embargo to the media at http://www.jamamedia.org.)

Editor’s Note: This study was supported by a training grant from the National Institutes of Health to the University of Texas Medical School at Houston Stroke Program. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Source: American Medical Association (AMA)

RELATED STORIES:
Simple procedure lowers blood pressure in kidney disease patients   WHO warns of high blood pressure, diabetes, obesity   Causes of hypertension start early, doctor warns   Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent   Changes in Gene Expression May Help Explain High Blood Pressure in Pregnancy   Swapping protein for sugar may help blood pressure   Drinking black tea may cut blood pressure   Middle-aged men with upper-normal blood pressure at risk for AF   Pollution tied to disease risk in L.A. black women   Birth Defects May be Linked to High Blood Pressure, Not Use of ACE Inhibitors   Poor sleep quality increases risk of high blood pressure   Pilot study suggests new approach to treat preeclampsia

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]